Close Breadcrumb Home 6 - What strategies are available for dose management in STIVARGA patients? What strategies are available for dose management in STIVARGA patients? 2022-10-18 Arturo Loaiza-Bonilla, MD, MSEd Enterprise Vice Chair of Medical Oncology, Enterprise Medical Director Cancer Treatment Centers of America - Any - Featured Efficacy Dosing MoA Patient Stories Toggle dropdown Videos filtered by: Proven Efficacy: Phase III CORRECT Data 2022-12-08 Please review the CORRECT data and video before viewing other videos What STIVARGA studies provide efficacy/safety data for patients with mCRC? 2022-10-18 John L. Marshall, MD Medical Oncologist Washington, D.C. What strategies are available for dose management in STIVARGA patients? 2022-10-18 Arturo Loaiza-Bonilla, MD, MSEd Enterprise Vice Chair of Medical Oncology, Enterprise Medical Director Cancer Treatment Centers of America Can you describe the mechanism of action for STIVARGA? 2022-10-18 Kanwal P.S. Raghav, MBBS, MD Medical Director, Division of Ambulatory Treatment Centers, MD Anderson Cancer Center (MDACC), The University of Texas, MDACC, Houston, TX Mimi’s story 2022-10-18 Mimi discusses her journey with metastatic colorectal cancer, including the events leading to her diagnosis, how she is educating others about the disease, the role of her family, and her decision to take STIVARGA Maria’s story 2022-10-18 Maria describes her experience with advanced colorectal cancer, including her diagnosis, treatment with STIVARGA, and how she manages side effects. She also shares her gratitude for her support system and for STIVARGA Video Categories (field_video_categories) - Any -FeaturedEfficacyDosingMoAPatient Stories Videos filtered by:
Proven Efficacy: Phase III CORRECT Data 2022-12-08 Please review the CORRECT data and video before viewing other videos
What STIVARGA studies provide efficacy/safety data for patients with mCRC? 2022-10-18 John L. Marshall, MD Medical Oncologist Washington, D.C.
What strategies are available for dose management in STIVARGA patients? 2022-10-18 Arturo Loaiza-Bonilla, MD, MSEd Enterprise Vice Chair of Medical Oncology, Enterprise Medical Director Cancer Treatment Centers of America
Can you describe the mechanism of action for STIVARGA? 2022-10-18 Kanwal P.S. Raghav, MBBS, MD Medical Director, Division of Ambulatory Treatment Centers, MD Anderson Cancer Center (MDACC), The University of Texas, MDACC, Houston, TX
Mimi’s story 2022-10-18 Mimi discusses her journey with metastatic colorectal cancer, including the events leading to her diagnosis, how she is educating others about the disease, the role of her family, and her decision to take STIVARGA
Maria’s story 2022-10-18 Maria describes her experience with advanced colorectal cancer, including her diagnosis, treatment with STIVARGA, and how she manages side effects. She also shares her gratitude for her support system and for STIVARGA